Accumulating evidence from contemporary oncological research has identified NT5E as a frequently upregulated ectoenzyme across diverse epithelial malignancies, with particularly pronounced overexpression observed in mammary carcinoma, colorectal adenocarcinoma, prostatic neoplasms, and ovarian epithelial cancers, suggesting its potential as a pan-cancer biomarker [30]. The gene discussed is NT5E; the disease is prostate neoplasm.